Latest Innovation News

CSL Limited reported robust FY25 results alongside a sweeping strategic overhaul, including a major cost-saving program and plans to spin off its vaccine unit CSL Seqirus as a standalone ASX-listed company.

CSL Limited posted a 14% rise in net profit for FY2025, underpinned by strong immunoglobulin sales and new product launches, while announcing plans to demerge its vaccines business, CSL Seqirus, to sharpen strategic focus.

Judo Capital Holdings Limited reported a robust FY25 with a 16% loan book expansion and a 14% rise in underlying profit before tax, underpinned by operational leverage and strategic regional growth.

ClearVue Technologies has responded to ASX concerns after its CEO described previous project pipeline announcements as ‘fairy tales,’ affirming prior disclosures were accurate despite some project setbacks.

Lake Resources has tapped its At-the-Market facility to raise A$1.575 million, aiming to fund key development stages of its flagship Kachi lithium project in Argentina.

Australian Bond Exchange Holdings has responded to ASX queries confirming the material impact of its involvement in the RBA's Project Acacia and acknowledged a director's breach of trading rules during a closed period.

Simonds Group delivered stable FY25 revenue and modest EBITDA growth despite one-off acquisition expenses, positioning itself for growth through strategic product and channel expansion in FY26.

Simonds Group Limited reported steady revenue of $665.6 million for FY2025, alongside a modest net profit of $1.015 million, as it completed the strategic acquisition of Dennis Family Homes. The company is focused on integrating the acquisition and driving growth amid a recovering housing market.

Bass Oil reported steady oil production in July alongside progress in acquiring the Vanessa gas field and advancing deep coal commercialisation efforts.

Regal Asian Investments Limited posted a sharp 92% decline in net profit for FY25 amid volatile Asian markets but maintained a fully franked 6 cent dividend and continued its on-market share buy-back program.

ReNerve Limited has achieved a key milestone with its first sale and clinical use of a deep dermal tissue product in the US, broadening its surgical applications beyond nerve repair. This move complements its existing nerve repair portfolio and sets the stage for further product launches later this year.

Rhythm Biosciences is raising up to $3.75 million through a share placement to fund the launch of its ColoSTAT® colorectal cancer diagnostic and accelerate commercialization of its geneType™ portfolio.